HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAsafety guidance84% confidence

Convenience Kit Correction: Medline Issues Correction for Kits Containing Huons Bupivacaine Hydrochloride in Dextrose Injection, USP

Source: FDA

Why This Matters

Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Medline; the same agency is already in play for this signal, so precedent weight is higher.

Regulatory Analysis

Medline is correcting affected convenience kits by removing recalled Bupivacaine Hydrochloride in Dextrose Injection components.

Supporting Context

Therapeutic area
Infection Control · Medical Devices
Sub-indication
General

Related signal: FDA Alerts on Non-Sterile BD ChloraPrep Applicators in Medline Convenience Kits

Source

View source document

Related Signal

Open signal — FDA Alerts on Non-Sterile BD ChloraPrep Applicators in Medline Convenience Kits
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.